Natural History Study of Patients With Hypophosphatasia (HPP)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorDuke University

About this trial

Hypophosphatasia (HPP) is a rare inherited metabolic disorder characterized by defective bone and teeth mineralization caused by mutations of the ALPL gene, which encodes for the tissue-nonspecific alkaline phosphatase (TNSALP) isozyme, resulting in decreased serum and bone alkaline phosphatase levels. To date, over 250 different mutations in the gene encoding TNSALP have been associated with HPP. Clinically, the loss of TNSALP function results in progressive skeletal impact as well as progressive impact on all other major organ systems. It clinically manifests as rickets in infants and children and osteomalacia at all ages. The severe form of the disease has been estimated to have a prevalence of about 1 in every 100,000 live births.

Eligibility criteria

Qualifiers

Patients or their legal representative must provide written informed consent or, if applicable, qualify for waiver of consent.

Serum alkaline phosphatase (ALP) below the age-adjusted normal range

Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination)

Evidence of osteopenia or osteomalacia on skeletal radiographs

Disqualifiers

Any patient without confirmation of clinical diagnosis of HPP.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

200 Participants
are grouped into 1 trial group

Sponsors and collaborators